Search results
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 5 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support...
Morningstar· 6 days agoTempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 5 days agoStudy participants had already received one hormone therapy and a type of drug called a CDK 4/6...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 days agoThe Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with AstraZeneca during BIO International ...
AstraZeneca’s breast cancer trial shows ‘unprecedented’ results | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 5 days agoAstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months...
Germany’s Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions – Interview
The Wall Street Journal· 5 hours agoMerck—known as EMD Group in the U.S.— is betting on artificial-intelligence partnerships to develop...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 4 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 4 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 day agoIn the first quarter, Wainua royalty revenues were $1 million. Wainua generated sales of $5 million...